REDWOOD CITY, Calif.--(BUSINESS WIRE)--Graybug Vision, Inc., a clinical stage pharmaceutical company committed to developing potentially transformative therapies for vision-threatening ocular diseases including wet age-related macular degeneration (wet AMD) and primary open angle glaucoma (POAG), today announced that data from its preclinical research will be highlighted in presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting, taking place from April 29 – May 3 in Honolulu, Hawaii.
Graybug Vision’s second-generation product, GB-103, is a potential once per year treatment of wet AMD. GB-103 follows Graybug Vision’s lead asset, GB-102, a clinical stage potential twice per year treatment of wet AMD, which is on track to complete enrollment of the first part of a Phase 1/2 study (ADAGIO study) of wet AMD patients in Q2 2018 and to present data at a scientific conference in Q4 2018. Both GB-102 and GB-103 are novel injectable depot formulations intended to gradually release sunitinib, a tyrosine kinase inhibitor that blocks angiogenesis pathways through multiple receptors (e.g., VEGFR receptors). The formulations are being developed to alleviate the treatment burden for wet AMD patients currently receiving intravitreal anti-VEGF agents into the eye every 6 to 8 weeks, on average.
Currently, the most common treatment of glaucoma is the use of eye drops that must be taken every day, and patients frequently forget or have difficulty administering these eye drops, leading to low medical compliance. Graybug Vision’s novel approach for glaucoma leverages its novel prodrug technology to create proprietary compounds combined with its depot delivery technology platform to provide sustained reductions in intraocular pressure for up to 6 months after injection potentially improving compliance and clinical outcomes.
On April 29th, Graybug Vision Senior Scientist Yun Yu, PhD, will present a poster titled: “Sunitinib-Loaded Injectable Polymer Depot Formulation for Potential Once per Year Treatment of Neovascular Age-related Macular Degeneration (wet AMD).”
On May 3rd, Graybug Vision Scientist Bryan Hoang, PhD, will present a poster titled: “An Injectable Depot Formulation of an Outflow Prodrug for Sustained Reduction of Intraocular Pressure.”
Details of the presentations are as follows:
Title: Sunitinib-Loaded Injectable Polymer Depot Formulation for Potential Once per Year Treatment of Neovascular Age-related Macular Degeneration (wet AMD)
Poster Number: 221 - C0032
Session Number: 111
Session Title: AMD
Date: April 29, 2018
Time: 8:15 AM to 10:00 AM
Title: An Injectable Depot Formulation of an Outflow Prodrug for Sustained Reduction of Intraocular Pressure
Poster Number: 5710 - A0429
Session Number: 516
Session Title: Drug and gene delivery systems
Date: May 3, 2018
Time: 8:15 AM to 10:00 AM
About Wet Age-related Macular Degeneration (wet AMD)
Wet (neovascular) age-related macular degeneration, is the leading cause of blindness in the developed world in individuals aged 50 years or older. It is caused by the formation of abnormal and leaky new blood vessels behind the retina, termed choroidal neovascularization. The leakage of fluid and protein from the vessels, causes retinal degeneration and leads to severe and rapid loss of vision. According to the National Eye Institute, the prevalence of wet AMD among adults 40 years or older in the U.S. alone is estimated at 1.75 million people. In addition, more than 200,000 new cases are diagnosed annually in the U.S.
About Primary Open Angle Glaucoma
Primary open angle glaucoma (POAG) is a leading cause of blindness worldwide. In POAG, a clear fluid (called aqueous humor) in the front of the eye passes too slowly through the meshwork drain in the open angle where the cornea and iris meet, causing the fluid to build up and increasing the intraocular pressure (IOP) in the eye. Several large studies have shown that elevated eye pressure is a major risk for damaging the optic nerve. When the optic nerve is damaged from increased pressure, vision loss may result. The only proven treatment to slow or halt progression of vision-loss in POAG is to reduce IOP, commonly with patient-administered eye drops.
About Graybug Vision
Graybug Vision is a clinical stage pharmaceutical company developing novel products for the treatment of ocular diseases. The company’s proprietary injectable products are designed to enable less frequent administration to reduce the burden of treatment for patients and their physicians. The company’s lead clinical-stage injectable product, GB-102, has the potential for twice per year dosing to treat patients with neovascular wet age related macular degeneration (wet AMD). Graybug Vision has also developed a library of preclinical compounds to treat primary open angle glaucoma (glaucoma) including potential best-in-class glaucoma agents with the potential for up to 6 months after a single injection. For more information, please visit www.graybug.com.